These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 4270696)

  • 1. Inhibitory effect of normal and cancerous tissues of the bladder on plasminogen activation.
    Hisazumi H
    Invest Urol; 1973 Nov; 11(3):258-62. PubMed ID: 4270696
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinolytic activity in normal and cancerous tissues of the bladder.
    Hisazumi H; Naito K; Misaki T
    Invest Urol; 1973 Jul; 11(1):28-34. PubMed ID: 4125063
    [No Abstract]   [Full Text] [Related]  

  • 3. Antifibrinolytic action of the anticoagulant split product of fibrinogen.
    Nanninga LB; Guest MM
    Thromb Diath Haemorrh; 1968 Jul; 19(3):526-32. PubMed ID: 5708130
    [No Abstract]   [Full Text] [Related]  

  • 4. Studies on the participation of Hageman factor in fibrinolysis.
    McDonagh RP; Ferguson JH
    Thromb Diath Haemorrh; 1970 Oct; 24(1):1-9. PubMed ID: 4249468
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on the mechanism of action of synthetic antifibrinolytics. A comparison with the action of derivatives of benzamidine on the fibrinolytic process.
    Landmann H
    Thromb Diath Haemorrh; 1973 May; 29(2):253-75. PubMed ID: 4271586
    [No Abstract]   [Full Text] [Related]  

  • 6. The influence of inhibitors of plasmin and plasminogen activation on the streptokinase-induced fibrinolytic state.
    Spöttl F; Holzknecht F
    Thromb Diath Haemorrh; 1970 Oct; 24(1):101-12. PubMed ID: 4249466
    [No Abstract]   [Full Text] [Related]  

  • 7. Release of fibrinopeptides from fibrinolytic fibrinogen fragment E.
    Peyer A; Straub PW
    Thromb Diath Haemorrh; 1973 May; 29(2):300-12. PubMed ID: 4271587
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrinolytic therapy: biochemical mechanisms.
    Robbins KC
    Semin Thromb Hemost; 1991 Jan; 17(1):1-6. PubMed ID: 1828622
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation and characterization of two fibrinolytic inhibitors from human placenta.
    Uszynski M; Abildgaard U
    Thromb Diath Haemorrh; 1971 Jun; 25(3):580-9. PubMed ID: 4998018
    [No Abstract]   [Full Text] [Related]  

  • 12. [Determination of serum inhibitors of fibrinolysis by the method of "standard clots"].
    Daver J; Albugues MJ; du Pasquier JP; Ricoeur M
    Pathol Biol (Paris); 1970; 18(11):687-94. PubMed ID: 4247466
    [No Abstract]   [Full Text] [Related]  

  • 13. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
    Li YJ; Zheng BZ; Zhou ZL
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assay of the antifibrinolytic activity in human plasma by means of the lysis time method.
    Ygge J; Berg W; Korsan-Bengtsen K
    Thromb Diath Haemorrh; 1968 Dec; 20(3):561-73. PubMed ID: 4237141
    [No Abstract]   [Full Text] [Related]  

  • 16. [Bladder wall permeability to to topically administered cisplatin].
    Zyrianov BN; Selivanov SP
    Urologiia; 2000; (5):28-30. PubMed ID: 11392221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method to correct for the continuing activation during the second stage in a two-stage assay. Exemplified by urokinase activation of plasminogen determined by the lysis time method.
    Berg W
    Thromb Diath Haemorrh; 1968 Mar; 19(1):161-8. PubMed ID: 4231459
    [No Abstract]   [Full Text] [Related]  

  • 18. ON THE INTERACTION OF FIBRINOLYSIN (PLASMIN) WITH THE INHIBITORS ANTIFIBRINOLYSIN AND SOYBEAN TRYPSIN INHIBITOR.
    NANNINGA LB; GUEST MM
    Arch Biochem Biophys; 1964 Dec; 108():542-51. PubMed ID: 14244698
    [No Abstract]   [Full Text] [Related]  

  • 19. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antiproteolytic and antifibrinolytic preparation obtained from the potato by means of chromatography on SE-sephadex C-50.
    Worowski K
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):617-32. PubMed ID: 4375312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.